GlassScriptPhysician profile
Christopher Jackson Reid
NPI 1821013079
$16,029.25
in general payments reported to CMS, 2019-2025
66 companies · $3,364 in 2025
The $3,364 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,691 · 2020: $789 · 2021: $312 · 2022: $1,697 · 2023: $3,452 · 2024: $3,724 · 2025: $3,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,240.36 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,395.17 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Abbvie INC. | $1,307.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,104.45 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,011.58 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $884.75 | 2019-2025 | |
| Emd Serono, INC. | $878.86 | 2019-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $840.80 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Csl Behring | $795.90 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $547.07 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $538.59 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Ucb, INC. | $531.94 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Eisai INC. | $475.91 | 2022-2025 | |
| Lundbeck LLC | $436.68 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $370.43 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $347.95 | 2019-2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.